The prime objective of the Boston University Alzheimer's Disease Center (BU ADC) is to provide resources to support high impact studies on the pathogenesis, detection, and treatment of Alzheimer's Disease (AD) and related disorders. The leadership team and investigators affiliated with the BU ADC represent a dynamic forward thinking team of clinicians and scientists who have made significant contributions to AD-related research and are committed to advancing the field in the years ahead. The BU ADC consists of an Administrative Core, Clinical Core, Data Management and Statistics Core, Neuropathology Core, Education and Information Transfer Core, and a Translational and Transgenic Core. The BU ADC has four aims.
Aim 1 is to foster and support high-impact, innovative, state of the art research on brain aging and AD by: a) identifying, recruiting, and thoroughly characterizing subjects willing to participate in clinical trials and other cutting-edge clinical research studies;b) collecting, storing, analyzing, and distribute biological samples to support high priority AD-related research;c) conducting state-of the-art diagnostic neuropathological evaluation and maximize CNS tissue donation to support state of the art tissue-based research;and d) fostering innovative AD research through a strong pilot project program.
Aim 2 is to collect and submit high quality data to the Data Management and Statistics Core for timely UDS submissions to the NACC database and for data sharing with qualified AD investigators engaged in cutting edge AD-related research while ensuring data security and integrity.
Aim 3 is to support and inform the communities we serve regarding the benefits of the BU ADC and AD research and to provide a high-quality training environment for professionals at all career levels. The BU ADC has developed innovative approaches to educate medical students about AD and has pioneered methods to increase African American brain donation.
Aim 4 is to breed and disseminate transgenic mouse models of AD and related disorders and to provide specialized technical services to support cutting edge translational AD-related research.

Public Health Relevance

Alzheimer's disease (AD) affects over 5 million people and is the 7th leading cause of death in the USA. Despite advances in understanding of how AD and other age-related diseases cause loss of brain function, much more research is needed on how AD and related disorders develop, how to detect them at their earliest stages, and how to treat them effectively once they develop. The mission of the Boston University Alzheimer's Disease Center is to provide resources to accelerate research addressing these vital questions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG013846-18
Application #
8501179
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M2))
Program Officer
Silverberg, Nina B
Project Start
1997-07-15
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
18
Fiscal Year
2013
Total Cost
$1,079,899
Indirect Cost
$222,836
Name
Boston University
Department
Neurology
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Armstrong, Richard A; McKee, Ann C; Alvarez, Victor E et al. (2017) Clustering of tau-immunoreactive pathology in chronic traumatic encephalopathy. J Neural Transm (Vienna) 124:185-192
Jutkowitz, Eric; Kane, Robert L; Gaugler, Joseph E et al. (2017) Societal and Family Lifetime Cost of Dementia: Implications for Policy. J Am Geriatr Soc 65:2169-2175
Moheb, Negar; Mendez, Mario F; Kremen, Sarah A et al. (2017) Executive Dysfunction and Behavioral Symptoms Are Associated with Deficits in Instrumental Activities of Daily Living in Frontotemporal Dementia. Dement Geriatr Cogn Disord 43:89-99
Cherry, Jonathan D; Stein, Thor D; Tripodis, Yorghos et al. (2017) CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer's disease. PLoS One 12:e0185541
Guan, Yue; Roter, Debra L; Erby, Lori H et al. (2017) Disclosing genetic risk of Alzheimer's disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. Patient Educ Couns 100:927-935
Montenigro, Philip H; Alosco, Michael L; Martin, Brett M et al. (2017) Cumulative Head Impact Exposure Predicts Later-Life Depression, Apathy, Executive Dysfunction, and Cognitive Impairment in Former High School and College Football Players. J Neurotrauma 34:328-340
Waring, J D; Dimsdale-Zucker, H R; Flannery, S et al. (2017) Effects of mild cognitive impairment on emotional scene memory. Neuropsychologia 96:240-248
Monsell, Sarah E; Mock, Charles; Fardo, David W et al. (2017) Genetic Comparison of Symptomatic and Asymptomatic Persons With Alzheimer Disease Neuropathology. Alzheimer Dis Assoc Disord 31:232-238
Mez, Jesse; Daneshvar, Daniel H; Kiernan, Patrick T et al. (2017) Clinicopathological Evaluation of Chronic Traumatic Encephalopathy in Players of American Football. JAMA 318:360-370
Mez, Jesse; Marden, Jessica R; Mukherjee, Shubhabrata et al. (2017) Alzheimer's disease genetic risk variants beyond APOE ?4 predict mortality. Alzheimers Dement (Amst) 8:188-195

Showing the most recent 10 out of 563 publications